Zaheer Ebtikar Joins Plasma as Chief Strategy Officer, Strengthening Leadership Ahead of Plasma One Launch
14.4.2026 17:10:00 CEST | Business Wire | Press Release
Plasma, the company behind the first stablecoin-native neobank and the infrastructure powering it, has announced the appointment of Zaheer Ebtikar as Chief Strategy Officer. The appointment reinforces Plasma's commitment to making stablecoins practical for everyday use worldwide, beginning with the launch of its stablecoin-native neobank, Plasma One.
Ebtikar brings more than eight years at the centre of crypto markets, combining macroeconomic insight with deep relationships across the institutional, trading, and infrastructure layers of the ecosystem. As Founder and Chief Investment Officer of Split Capital, he built one of crypto's most prominent hedge funds. He has also held senior roles at LedgerPrime, Deribit, and Immutable Capital.
The global stablecoin supply has nearly doubled in the past year. Institutions worldwide are racing to define their strategies, yet no product has bridged the gap between stablecoin infrastructure and a full consumer banking experience. Plasma One is designed to be exactly that: the first stablecoin-native neobank, turning stablecoins into a practical tool for everyday spending, saving, and business use across markets.
To support that ambition, Plasma is building a vertically integrated licensing and technology stack, acquiring regulatory licenses in key markets and bringing critical infrastructure in-house. This own-the-stack approach is designed to deliver lower costs, greater reliability, and a defensible long-term position in an increasingly competitive landscape.
Chief Strategy Officer, Zaheer Ebtikar, said: "I remember visiting the Grand Bazaar in Istanbul and seeing the sheer volume of over-the-counter transactions between cash, lira and USD₮. That moment made clear to me that stablecoins aren't a niche, they're becoming the backbone of how people actually move money. What drew me to Plasma is that they're not just building another chain. They're building the first product that puts a stablecoin-powered banking service in anyone's hands, and assembling the licensing infrastructure to make it work at scale."
CEO, Paul Faecks, said: "Zaheer brings a rare combination of deep market intuition, institutional credibility, and genuine conviction in what we're building. As we move from mainnet to product launch, his strategic leadership will be critical in driving Plasma One into the hands of users worldwide."
About Plasma
Plasma builds financial products for consumers and businesses using stablecoins instead of traditional banking rails. Plasma One, its first product, lets users send, spend, save, and earn with stablecoins. Everything runs on Plasma's own blockchain, built from the ground up for speed, reliability, and scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414131900/en/
Contacts
Kishan Naran - kishan.naran@wachsman.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
TestMu AI and Quarks Technosoft Partner to Power the Next Era of Autonomous Quality Engineering14.4.2026 18:00:00 CEST | Press Release
TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced a strategic partnership with Quarks Technosoft, a leading digital engineering and quality consulting firm, to redefine how enterprises approach software testing in the age of AI-driven development. As organizations increasingly adopt AI to generate code at unprecedented speed, traditional testing models are emerging as the primary constraint to innovation. This partnership brings together TestMu AI’s autonomous testing capabilities and Quarks Technosoft’s deep expertise in quality engineering transformation to create a unified, future-ready approach to software quality, one that is intelligent, scalable, and enterprise-grade. At the core of this collaboration is a shared vision to enable Autonomous Quality Engineering, where testing evolves from a manual, reactive function into a self-governing, continuously learning system. TestMu AI delivers the intelligence layer th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom